Chris Labaki

Chris Labaki

Auto-generated profile, based on publicly available information

Chris Labaki

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Cell Reports
Verified
Journal Article
Open access
ZBZiad Bakouny
Ziad Bakouny
ASAnanthan Sadagopan
Ananthan Sadagopan
PRPraful Ravi
Praful Ravi
NMNebiyou Y. Metaferia
Nebiyou Y. Metaferia
JLJiao Li
Jiao Li
SVSrinivas R. Viswanathan
Srinivas R. Viswanathan
Translocation renal cell carcinoma (tRCC) is a poorly-characterized subtype of kidney cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of tRCC through an integrative analysis of 152 patients with tRCC identified across genomic, clinical trial, and retrospective cohorts. Most tRCCs harbor few somatic alterations apart from MiT/TFE fusions and homozygous deletions at chromosome 9p21.3 (19.2% of cases). Transcriptionally, tRCCs display a heightened NRF2-driven antioxidant response that is associated with resistance to targeted therapies. Consistently, we find that outcomes for patients with tRCC treated with vascular endothelial growth factor receptor inhibitors (VEGFR-TKI) are worse than those treated with immune checkpoint inhibition (ICI). Using multiparametric immunofluorescence, we find that the tumors are infiltrated with CD8+ T cells, though the T cells harbor an exhaustion immunophenotype distinct from that of clear cell RCC. Our findings comprehensively define the clinical and molecular features of tRCC and may inspire new therapeutic hypotheses.

2 August 2021 in Future Oncology
Verified
Journal Article
Open access
EMElissar Moujaes
Elissar Moujaes
NZNaji Bou Zeid
Naji Bou Zeid
RSRamy Samaha
Ramy Samaha
JSJoud Sawan
Joud Sawan
HKHampig Kourie
Hampig Kourie
JKJoseph Kattan
Joseph Kattan
Aims: This paper reports the results of a survey assessing the acceptance of the coronavirus disease 2019 (COVID-19) vaccine among patients with cancer. Patients and methods: In total, 111 adult pa... Lay abstract Major cancer societies consider vaccinating patients with cancer against coronavirus disease 2019 (COVID-19) a priority. The investigators conducted a survey assessing perceptions of t...

9 January 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
TJTejas Jammihal
Tejas Jammihal
RSRenee Maria Saliby
Renee Maria Saliby
CLChris Labaki
Chris Labaki
HSHanna Soulati
Hanna Soulati
JGJuan Gallegos
Juan Gallegos
SSSachet A. Shukla
Sachet A. Shukla

13 February 2023 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
TCToni K. Choueiri
Toni K. Choueiri
CLChris Labaki
Chris Labaki
ZBZiad Bakouny
Ziad Bakouny
CHChih-Yuan Hsu
Chih-Yuan Hsu
ASAndrew L. Schmidt
Andrew L. Schmidt
JWJeremy L. Warner
Jeremy L. Warner
Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to have worse outcomes associated with COVID-19 during the pandemic. We sought to evaluate the clinical characteristics and outcomes of patients with cancer who developed breakthrough SARS-CoV-2 infections after 2 or 3 doses of mRNA vaccines. We evaluated the clinical characteristics of patients with cancer who developed breakthrough infections using data from the multi-institutional COVID-19 and Cancer Consortium (CCC19; NCT04354701). Analysis was restricted to patients with laboratory-confirmed SARS-CoV-2 diagnosed in 2021 or 2022, to allow for a contemporary unvaccinated control population; potential differences were evaluated using a multivariable logistic regression model after inverse probability of treatment weighting to adjust for potential baseline confounding variables. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) are reported. The primary endpoint was 30-day mortality, with key secondary endpoints of hospitalization and ICU and/or mechanical ventilation (ICU/MV). The analysis included 2486 patients, of which 564 and 385 had received 2 or 3 doses of an mRNA vaccine prior to infection, respectively. Hematologic malignancies and recent receipt of systemic anti-neoplastic therapy were more frequent among vaccinated patients. Vaccination was associated with improved outcomes: in the primary analysis, 2 doses (aOR: 0.62, 95% CI: 0.44-0.88) and 3 doses (aOR: 0.20, 95% CI: 0.11-0.36) were associated with decreased 30-day mortality. There were similar findings for the key secondary endpoints of ICU/MV (aOR: 0.60, 95% CI: 0.45-0.82 and 0.37, 95% CI: 0.24-0.58) and hospitalization (aOR: 0.60, 95% CI: 0.48-0.75 and 0.35, 95% CI: 0.26-0.46) for 2 and 3 doses, respectively. Importantly, Black patients had higher rates of hospitalization (aOR: 1.47, 95% CI: 1.12-1.92), and Hispanic patients presented with higher rates of ICU/MV (aOR: 1.61, 95% CI: 1.06-2.44). Vaccination against COVID-19, especially with additional doses, is a fundamental strategy in the prevention of adverse outcomes including death, among patients with cancer. This study was partly supported by grants from the National Cancer Institute grant number P30 CA068485 to C-YH, YS, SM, JLW; T32-CA236621 and P30-CA046592 to C.R.F; CTSA 2UL1TR001425-05A1 to TMW-D; ACS/FHI Real-World Data Impact Award, P50 MD017341-01, R21 CA242044-01A1, Susan G. Komen Leadership Grant Hunt to MKA. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH).

16 December 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TDThomas Denize
Thomas Denize
SFSubrina Farah
Subrina Farah
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
AFAbdallah Flaifel
Abdallah Flaifel
EWEmily Walton
Emily Walton
SSSabina Signoretti
Sabina Signoretti
Purpose: Antiangiogenic VEGF receptor (VEGFR) inhibitors are approved for metastatic clear cell renal cell carcinoma (mccRCC) and their efficacy is higher in high angiogenic tumors. As cabozantinib inhibits multiple tyrosine kinase receptors, including VEGFRs, we tested whether markers of angiogenesis, including microvascular density (MVD) and mast cell density (MCD), could predict benefit from cabozantinib versus everolimus, using RCC samples from the METEOR (NCT01865747) trial. Experimental Design: MVD and MCD were studied in 430 patients (cabozantinib = 216, everolimus = 214) by double immunohistochemistry for CD31 (vascular marker) and tryptase (mast cell marker) coupled with automated image analysis. Results from evaluable cases (MVD = 360, MCD = 325) were correlated with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). Results: MVD was positively correlated with MCD. In the whole cohort, high MVD and high MCD were associated with longer PFS; improved PFS was most evident in patients with high levels of both MCD and MVD. Cabozantinib was associated with improved PFS, OS, and ORR compared with everolimus, irrespective of MVD levels. Cabozantinib was also associated with improved ORR compared with everolimus, irrespective of MCD levels. For PFS and OS, the treatment effect for cabozantinib versus everolimus tended to be greater in tumors with low MCD. Conclusions: High MVD and high MCD are associated with improved outcome in mccRCC but do not predict efficacy to cabozantinib versus everolimus. The high efficacy of cabozantinib in low angiogenic tumors allows us to speculate that its antitumor activity is not exclusively mediated by VEGFR inhibition.

1 March 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
TCToni K. Choueiri
Toni K. Choueiri
LALaurence Albiges
Laurence Albiges
MAMichael B Atkins
Michael B Atkins
ZBZiad Bakouny
Ziad Bakouny
GBGennady Bratslavsky
Gennady Bratslavsky
HHHans J. Hammers
Hans J. Hammers
The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.